Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Combinatorial Chemistry & High Throughput Screening
  4. Fast Track Articles
  5. Fast Track Article
image of Preparation of DOX-TPP/HA-ss-OA Nanoparticles, Investigation of Drug Release Behavior In Vitro, and Evaluation of Anti-proliferative Activity In Vitro

Abstract

Objective

This study aimed to develop and characterize DOX-TPP/HA-ss-OA nanoparticles, utilizing the mitochondria-targeting prodrug doxorubicin-triphenylphosphine (DOX-TPP) and a reduction-sensitive amphiphilic polymer, hyaluronic acid-disulfide-oleic acid (HA-ss-OA). The research focused on evaluating the drug release behavior of these nanoparticles under varying glutathione (GSH) concentrations and their anti-tumor activity .

Methods

DOX-TPP/HA-ss-OA nanoparticles were prepared using probe ultrasound technology. The study examined the impact of different organic solvents on drug loading capacity and encapsulation efficiency to determine the optimal conditions. A single-factor experimental design was used to optimize the formulation process. Key parameters, including particle size and zeta potential, were measured to assess nanoparticle stability and performance. The dynamic dialysis method was employed to evaluate the reduction-sensitive drug release characteristics in media with different GSH concentrations. The MTT assay was used to analyze the growth-inhibitory effects of the nanoparticles on human breast cancer cells (MCF-7) and drug-resistant cells (MCF-7/ADR).

Results

The optimized preparation process for DOX-TPP/HA-ss-OA nanoparticles included a drug dosage of 2.0 mg, an oil-to-water volume ratio of 1:5, ultrasonic power of 500 W, and ultrasonic time of 15 minutes. The nanoparticles had an average particle size of 203.72 ± 2.30 nm and a zeta potential of 25.82 ± 0.58 mV, indicating favorable stability and effective drug delivery properties. The nanoparticles exhibited a slow, sustained release of DOX-TPP in pH 7.4 phosphate buffer solution (PBS) and accelerated release in high GSH concentrations, demonstrating reduction-responsive drug release. studies showed that DOX-TPP/HA-ss-OA nanoparticles significantly inhibited the proliferation of MCF-7 and MCF-7/ADR cells in a dose-dependent manner, with enhanced efficacy compared to free DOX and other formulations.

Conclusion

DOX-TPP/HA-ss-OA nanoparticles demonstrate excellent reduction sensitivity, effective tumor cell growth inhibition , and the ability to overcome drug resistance. Including particle size and zeta potential measurements supports their suitability as drug carriers, highlighting their potential for targeted cancer therapy and further development.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cchts/10.2174/0113862073330016240911094247
2024-11-06
2025-03-01

  • From This Site

    /content/journals/cchts/10.2174/0113862073330016240911094247
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Allemani C. Matsuda T. Di Carlo V. Harewood R. Matz M. Nikšić M. Bonaventure M. Valkov M. Johnson CJ. Estève J. Global surveillance of trends in cancer survival: Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers during 2000–2014 from 322 population-based registries in 71 countries (CONCORD-3). Lancet 2018 391 10125 1023 10.1016/S0140‑6736(17)33326‑3 29395269
    [Google Scholar]
  2. Ramachandran M. Ma Z. Lin K. De Souza C. Li Y. Transformable nanoparticles to bypass biological barriers in cancer treatment. Nanoscale Adv. 2022 4 21 4470 4480 10.1039/D2NA00485B 36341301
    [Google Scholar]
  3. Wang X. Li C. Wang Y. Chen H. Zhang X. Luo C. Zhou W. Li L. Teng L. Yu H. Wang J. Smart drug delivery systems for precise cancer therapy. Acta Pharm. Sin. B 2022 12 11 4098 4121 10.1016/j.apsb.2022.08.013 36386470
    [Google Scholar]
  4. Rasool M. Malik A. Waquar S. Arooj M. Zahid S. Asif M. Shaheen S. Hussain A. Ullah H. Gan S.H. New challenges in the use of nanomedicine in cancer therapy. Bioengineered 2022 13 1 759 773 10.1080/21655979.2021.2012907 34856849
    [Google Scholar]
  5. Brown S.A. Ray J.C. Herrmann J. Precision Cardio-Oncology: A systems-based perspective on cardiotoxicity of tyrosine kinase inhibitors and immune checkpoint inhibitors. J. Cardiovasc. Transl. Res. 2020 13 3 402 416 10.1007/s12265‑020‑09992‑5 32253744
    [Google Scholar]
  6. Murphy M.P. Hartley R.C. Mitochondria as a therapeutic target for common pathologies. Nat. Rev. Drug Discov. 2018 17 12 865 886 10.1038/nrd.2018.174 30393373
    [Google Scholar]
  7. Garcia-Ruiz C. Conde de la Rosa L. Ribas V. Fernandez-Checa J.C. Mitochondrial cholesterol and cancer. Semin. Cancer Biol. 2021 73 76 85 10.1016/j.semcancer.2020.07.014 32805396
    [Google Scholar]
  8. Saha S. Saso L. Armagan G. Cancer prevention and therapy by targeting oxidative stress pathways. Molecules 2023 28 11 4293 10.3390/molecules28114293
    [Google Scholar]
  9. Joshi A. Ito T. Picard D. Neckers L. The Mitochondrial HSP90 Paralog TRAP1: Structural Dynamics, Interactome, Role in Metabolic Regulation, and Inhibitors. Biomolecules 2022 12 7 880 10.3390/biom12070880 35883436
    [Google Scholar]
  10. Imstepf S. Pierroz V. Rubbiani R. Felber M. Fox T. Gasser G. Alberto R. Organometallic Rhenium Complexes Divert Doxorubicin to the Mitochondria. Angew. Chem. Int. Ed. 2016 55 8 2792 2795 10.1002/anie.201511432 26799241
    [Google Scholar]
  11. Cheng X. Feng D. Lv J. Cui X. Wang Y. Wang Q. Zhang L. Application prospects of triphenylphosphine-based mitochondria-targeted cancer therapy. Cancers (Basel) 2023 15 3 666 10.3390/cancers15030666
    [Google Scholar]
  12. Liu Y. Zhang X. Zhou M. Nan X. Chen X. Zhang X. Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance. ACS Appl. Mater. Interfaces 2017 9 50 43498 43507 10.1021/acsami.7b14577 29171954
    [Google Scholar]
  13. Lammers T. Hennink W. Storm G. Nanomedicine: Principles, Properties, and Perspectives. Adv. Drug Deliv. Rev. 2012 64 2 106 117 10.1016/j.addr.2011.03.005
    [Google Scholar]
  14. Wang H. Zhao X. Wang Y. Development of a Nanoparticle Platform for the Targeted Delivery of Lipophilic Anticancer Drugs. J. Biomed. Nanotechnol. 2013 9 5 856 864 10.1166/jbn.2013.1537 23802416
    [Google Scholar]
  15. Li Y. Zheng L. Yang H. Formamide as an Efficient Solvent in the Preparation of Nanoparticles for Drug Delivery. Colloids Surf. B Biointerfaces 2015 130 61 68 10.1016/j.colsurfb.2015.03.008
    [Google Scholar]
  16. Zeng X. Sun Z. Liu J. Factors influencing the encapsulation efficiency and drug loading capacity of polymeric nanoparticles. J. Nanosci. Nanotechnol. 2013 13 1 435 442 10.1166/jnn.2013.6970
    [Google Scholar]
  17. Zhang Z. Yang Q. Wang L. Optimization of nanoparticle formulation for enhanced drug loading and encapsulation efficiency. Int. J. Pharm. 2014 470 1–2 210 219 10.1016/j.ijpharm.2014.04.028 24508807
    [Google Scholar]
  18. Yang Y. Shi Z. Huang W. Reduction-responsive nanoparticles for controlled drug delivery. J. Control. Release 2014 193 150 157 10.1016/j.jconrel.2014.05.002
    [Google Scholar]
  19. Fang J. Nakamura H. Maeda H. Tumor-selective delivery of doxorubicin via reduction-sensitive polymeric micelles. Biomacromolecules 2011 12 5 1446 1454 10.1021/bm2000815 21413697
    [Google Scholar]
  20. Zhao Y. Liu T. Wang X. Reduction-Sensitive Nanoparticles for Targeted Drug Delivery. Adv. Mater. 2013 25 4 591 595 10.1002/adma.201203578 23081662
    [Google Scholar]
  21. Shen Y. Jin W. Hu P. Mitochondrial Targeting Nanoparticles for Cancer Therapy. ACS Nano 2016 10 2 500 510 10.1021/acsnano.5b06309 26649888
    [Google Scholar]
  22. Zhang Q. Gao X. Li H. Mitochondrial-Targeted Nanoparticles for Enhanced Cancer Therapy. J. Nanobiotechnology 2017 15 1 12 10.1186/s12951‑017‑0247‑1 28173812
    [Google Scholar]
  23. Dong X. Zhang Z. Li Q. Overcoming Multidrug Resistance in Cancer: Nanoparticle-Based Strategies. Acta Pharm. Sin. B 2014 4 3 160 167 10.1016/j.apsb.2014.04.004
    [Google Scholar]
  24. Wang F. Song Z. Zhao X. Nanoparticle-Based Drug Delivery Systems: Promising Approaches to Overcome Drug Resistance in Cancer Therapy. J. Exp. Clin. Cancer Res. 2015 34 1 2 10.1186/1756‑9966‑31‑2 25591549
    [Google Scholar]
  25. Moghimi S.M. Hunter C. Capture of stealth nanoparticles by the body’s defences. Crit. Rev. Ther. Drug Carrier Syst. 2001 18 6 24 10.1615/CritRevTherDrugCarrierSyst.v18.i6.30 11789674
    [Google Scholar]
  26. Patel S. Upconversion nanoparticles in bioassays, optical imaging and therapy. J. Nanosci. Nanotechnol. 2014 14 1 170 182 10.1166/jnn.2014.8894
    [Google Scholar]
  27. Zhang L. Fe–Cr–Nb–B magnetic nanoparticle interaction with human mesenchymal and stem cells. J. Biomed. Nanotechnol. 2017 13 3 254 266 10.1166/jbn.2017.2389
    [Google Scholar]
  28. Gao Y. Lin H. Yang Z. Evaluation of Nanoparticle Properties for Targeted Drug Delivery. J. Nanotechnol. 2020 15 6 112 124 10.1016/j.jnano.2020.112124
    [Google Scholar]
/content/journals/cchts/10.2174/0113862073330016240911094247
Loading
Preparation of DOX-TPP/HA-ss-OA Nanoparticles, Investigation of Drug Release Behavior In Vitro, and Evaluation of Anti-proliferative Activity In Vitro
Bentham Science Publishers ; https://doi.org/10.2174/0113862073330016240911094247
/content/journals/cchts/10.2174/0113862073330016240911094247
/content/journals/cchts/10.2174/0113862073330016240911094247
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: doxorubicin-triphenylphosphine ; DOX-TPP/HA-ss-OA nanoparticles ; anti-tumor activity ; reduction responsiveness ; drug release behavior

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test